These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 29652893)

  • 1. Glucose sensor-augmented continuous subcutaneous insulin infusion in patients with diabetic gastroparesis: An open-label pilot prospective study.
    Calles-Escandón J; Koch KL; Hasler WL; Van Natta ML; Pasricha PJ; Tonascia J; Parkman HP; Hamilton F; Herman WH; Basina M; Buckingham B; Earle K; Kirkeby K; Hairston K; Bright T; Rothberg AE; Kraftson AT; Siraj ES; Subauste A; Lee LA; Abell TL; McCallum RW; Sarosiek I; Nguyen L; Fass R; Snape WJ; Vaughn IA; Miriel LA; Farrugia G;
    PLoS One; 2018; 13(4):e0194759. PubMed ID: 29652893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Satiety testing in diabetic gastroparesis: Effects of insulin pump therapy with continuous glucose monitoring on upper gastrointestinal symptoms and gastric myoelectrical activity.
    Koch KL; Hasler WL; Van Natta M; Calles-Escandon J; Grover M; Pasricha PJ; Snape WJ; Parkman HP; Abell TL; McCallum RW; Nguyen LA; Sarosiek I; Farrugia G; Tonascia J; Lee L; Miriel L; Hamilton F;
    Neurogastroenterol Motil; 2020 Jan; 32(1):e13720. PubMed ID: 31574209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained efficacy of continuous subcutaneous insulin infusion in type 1 diabetes subjects with recurrent non-severe and severe hypoglycemia and hypoglycemia unawareness: a pilot study.
    Giménez M; Lara M; Conget I
    Diabetes Technol Ther; 2010 Jul; 12(7):517-21. PubMed ID: 20597825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-time continuous glucose monitoring or continuous subcutaneous insulin infusion, what goes first?: results of a pilot study.
    Moreno-Fernandez J; Gomez FJ; Gazquez M; Pedroche M; García-Manzanares A; Tenias JM; Benito P; Gomez IR
    Diabetes Technol Ther; 2013 Jul; 15(7):596-600. PubMed ID: 23631604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of an algorithm to guide patients with type 1 diabetes treated with continuous subcutaneous insulin infusion on how to respond to real-time continuous glucose levels: a randomized controlled trial.
    Jenkins AJ; Krishnamurthy B; Best JD; Cameron FJ; Colman PG; Farish S; Hamblin PS; O'Connell MA; Rodda C; Rowley K; Teede H; O'Neal DN
    Diabetes Care; 2010 Jun; 33(6):1242-8. PubMed ID: 20215457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study.
    Garg SK; Voelmle MK; Beatson CR; Miller HA; Crew LB; Freson BJ; Hazenfield RM
    Diabetes Care; 2011 Mar; 34(3):574-9. PubMed ID: 21278138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study.
    Camilleri M; McCallum RW; Tack J; Spence SC; Gottesdiener K; Fiedorek FT
    Gastroenterology; 2017 Nov; 153(5):1240-1250.e2. PubMed ID: 28760384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.
    Rodbard D
    Diabetes Technol Ther; 2017 Jun; 19(S3):S25-S37. PubMed ID: 28585879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
    Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
    J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting.
    Alamoudi R; Alsubaiee M; Alqarni A; Saleh Y; Aljaser S; Salam A; Eledrisi M
    Diabetes Technol Ther; 2017 Jun; 19(6):349-354. PubMed ID: 28296467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study.
    Šoupal J; Petruželková L; Flekač M; Pelcl T; Matoulek M; Daňková M; Škrha J; Svačina Š; Prázný M
    Diabetes Technol Ther; 2016 Sep; 18(9):532-8. PubMed ID: 27482825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experiences of continuous subcutaneous insulin infusion in pregnant women with type 1 diabetes during delivery from four Italian centers: a retrospective observational study.
    Fresa R; Visalli N; Di Blasi V; Cavallaro V; Ansaldi E; Trifoglio O; Abbruzzese S; Bongiovanni M; Agrusta M; Napoli A
    Diabetes Technol Ther; 2013 Apr; 15(4):328-34. PubMed ID: 23537417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis.
    Ejskjaer N; Vestergaard ET; Hellström PM; Gormsen LC; Madsbad S; Madsen JL; Jensen TA; Pezzullo JC; Christiansen JS; Shaughnessy L; Kosutic G
    Aliment Pharmacol Ther; 2009 Jun; 29(11):1179-87. PubMed ID: 19298585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of symptoms, syndrome and disease: treatment of refractory diabetic gastroparesis.
    Li JL; Li M; Pang B; Zhou Q; Tian JX; Liu HX; Zhao XY; Tong XL
    World J Gastroenterol; 2014 Jul; 20(26):8674-80. PubMed ID: 25024625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
    Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
    Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial: a controlled pilot trial of the 5-HT4 receptor agonist revexepride in patients with symptoms suggestive of gastroparesis.
    Tack J; Rotondo A; Meulemans A; Thielemans L; Cools M
    Neurogastroenterol Motil; 2016 Apr; 28(4):487-97. PubMed ID: 27010235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus.
    Lacy BE; Crowell MD; Schettler-Duncan A; Mathis C; Pasricha PJ
    Diabetes Care; 2004 Oct; 27(10):2341-7. PubMed ID: 15451898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rate of Change of Premeal Glucose Measured by Continuous Glucose Monitoring Predicts Postmeal Glycemic Excursions in Patients With Type 1 Diabetes: Implications for Therapy.
    Majithia AR; Wiltschko AB; Zheng H; Walford GA; Nathan DM
    J Diabetes Sci Technol; 2018 Jan; 12(1):76-82. PubMed ID: 28868899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous glucose monitoring in gastroparesis.
    Ramzan Z; Duffy F; Gomez J; Fisher RS; Parkman HP
    Dig Dis Sci; 2011 Sep; 56(9):2646-55. PubMed ID: 21735078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.